Display options
Cite
Vedin AM, Karlsson H, Fink C, et al. Presenting features and long-term effects of growth hormone treatment of children with optic nerve hypoplasia/septo-optic dysplasia. Int J Pediatr Endocrinol. 2011;2011(1):17doi: 10.1186/1687-9856-2011-17.
Vedin, A. M., Karlsson, H., Fink, C., Borchert, M., & Geffner, M. E. (2011). Presenting features and long-term effects of growth hormone treatment of children with optic nerve hypoplasia/septo-optic dysplasia. International journal of pediatric endocrinology, 2011(1), 17. https://doi.org/10.1186/1687-9856-2011-17
Vedin, Amy M, et al. "Presenting features and long-term effects of growth hormone treatment of children with optic nerve hypoplasia/septo-optic dysplasia." International journal of pediatric endocrinology vol. 2011,1 (2011): 17. doi: https://doi.org/10.1186/1687-9856-2011-17
Vedin AM, Karlsson H, Fink C, Borchert M, Geffner ME. Presenting features and long-term effects of growth hormone treatment of children with optic nerve hypoplasia/septo-optic dysplasia. Int J Pediatr Endocrinol. 2011 Nov 15;2011(1):17. doi: 10.1186/1687-9856-2011-17. PMID: 22085631; PMCID: PMC3256097.
Copy Download .nbib Format: NLM
Share it on

Int J Pediatr Endocrinol. 2011 Nov 15;2011(1):17. doi: 10.1186/1687-9856-2011-17.

Presenting features and long-term effects of growth hormone treatment of children with optic nerve hypoplasia/septo-optic dysplasia.

International journal of pediatric endocrinology

Amy M Vedin, Hanna Karlsson, Cassandra Fink, Mark Borchert, Mitchell E Geffner

Affiliations

  1. Center for Endocrinology, Diabetes, and Metabolism, Children's Hospital Los Angeles, 4650 Sunset Boulevard, Mailstop #61, Los Angeles, CA 90027, USA. [email protected].

PMID: 22085631 PMCID: PMC3256097 DOI: 10.1186/1687-9856-2011-17

Abstract

BACKGROUND: Optic nerve hypoplasia (ONH) with/or without septo-optic dysplasia (SOD) is a known concomitant of congenital growth hormone deficiency (CGHD).

METHODS: Demographic and longitudinal data from KIGS, the Pfizer International Growth Database, were compared between 395 subjects with ONH/SOD and CGHD and 158 controls with CGHD without midline pathology.

RESULTS: ONH/SOD subjects had higher birth length/weight, and mid-parental height SDS. At GH start, height, weight, and BMI SDS were higher in the ONH/SOD group. After 1 year of GH, both groups showed similar changes in height SDS, while weight and BMI SDS remained higher in the ONH/SOD group. The initial height responses of the two groups were similar to those predicted using the KIGS-derived prediction model for children with idiopathic GHD. At near-adult height, ONH/SOD and controls had similar height, weight, and BMI SDS.

CONCLUSIONS: Compared to children with CGHD without midline defects, those with ONH/SOD presented with greater height, weight, and BMI SDS. These differences persisted at 1 year of GH therapy, but appeared to be overcome by long-term GH treatment.

References

  1. J Pediatr. 2006 Jan;148(1):85-8 - PubMed
  2. Arch Dis Child. 1995 Jul;73(1):17-24 - PubMed
  3. J Pediatr Endocrinol Metab. 2002 May;15 Suppl 2:697-700 - PubMed
  4. Helv Paediatr Acta Suppl. 1989 Jun;52:1-125 - PubMed
  5. Curr Neurol Neurosci Rep. 2008 Sep;8(5):395-403 - PubMed
  6. Eur J Hum Genet. 2010 Apr;18(4):393-7 - PubMed
  7. Arch Ophthalmol. 1993 Jan;111(1):66-74 - PubMed
  8. Acta Paediatr Scand. 1991 Aug-Sep;80(8-9):756-62 - PubMed
  9. J Pediatr. 2006 Jan;148(1):78-84 - PubMed
  10. J Clin Endocrinol Metab. 1999 Apr;84(4):1174-83 - PubMed
  11. Arch Dis Child. 1983 Oct;58(10):767-76 - PubMed

Publication Types